10-Q: Femasys Reports Q3 Revenue Growth Amidst Rising Losses

Femasys Inc. reported a 31.4% increase in Q3 2025 sales, driven by FemBloc, but saw net losses widen for the nine-month period and faces ongoing liquidity and Nasdaq compliance challenges.

Summary

• Sales for the three months ended September 30, 2025, increased by 31.4% to $729,394, up from $554,908 in the prior year, primarily due to FemBloc sales.
• Sales for the nine months ended September 30, 2025, increased by 41.3% to $1,479,926, compared to $1,047,532 in the prior year, driven by FemBloc and FemVue.
• Net loss for the three months ended September 30, 2025, decreased by 22.4% to $(4,194,821) from $(5,408,860) in the prior year.
• Net loss for the nine months ended September 30, 2025, increased by 7.2% to $(14,677,582) from $(13,692,944) in the prior year.
• Cash and cash equivalents stood at $4,569,038 as of September 30, 2025, up from $3,451,761 at December 31, 2024.
• The company has an accumulated deficit of $141,875,839 as of September 30, 2025.
• Research and development expenses decreased by 40.0% for the three-month period and 4.7% for the nine-month period, mainly due to commercialization of development products and reduced clinical/professional fees.
• Femasys received FDA approval in November 2025 for its IDE supplement to advance FemBloc to the final phase of its pivotal clinical trial for U.S. approval.
• FemBloc received CE mark certification in the EU in March and June 2025, and UK and New Zealand regulatory approvals in August and September 2025, respectively.
• Strategic distribution partnerships for FemBloc were announced in Spain (March 2025) and France/Benelux region (September 2025).
• The company introduced FemSperm, a new kit for in-office sperm preparation and analysis for use with FemaSeed, and partnered with Medical Electronic Systems LLC (MES).
• Femasys faces substantial doubt about its ability to continue as a going concern, with current cash and recent financing expected to fund operations only into September 2026, not for a full 12 months from the filing date.
• The company received Nasdaq deficiency letters regarding non-compliance with the Minimum Market Value of Listed Securities (MVLS) and Minimum Bid Price requirements, with a grace period until January 12, 2026, to regain bid price compliance.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to increasing net losses over the nine-month period, a high cash burn rate, explicit 'going concern' doubt, and significant Nasdaq delisting risks. While there are positives like revenue growth and product approvals, these are overshadowed by the severe financial and operational challenges, including the need for continuous capital raises that dilute shareholders and primarily serve to repay existing debt rather than fund new growth.

Positives

• Total sales increased by 31.4% for the three months and 41.3% for the nine months ended September 30, 2025, driven by FemBloc and FemVue.
• Net loss for the three months ended September 30, 2025, decreased by 22.4% compared to the same period in 2024.
• FemBloc received significant international regulatory approvals, including CE mark certification in the EU (March and June 2025), UK (August 2025), and New Zealand (September 2025).
• FDA IDE approval was granted in November 2025 for FemBloc to proceed to the final phase of its pivotal U.S. clinical trial.
• Strategic distribution partnerships for FemBloc were established in Spain and the France/Benelux region, expanding commercial reach.
• The introduction of FemSperm kits enhances the FemaSeed infertility portfolio, enabling in-office sperm preparation and analysis.
• Research and development expenses decreased, indicating a shift towards commercialization and potentially more efficient spending.
• The company successfully raised significant capital through multiple financings in June, August, and November 2025, and warrant exercises, providing necessary liquidity.

Negatives

• Net loss for the nine months ended September 30, 2025, increased by 7.2% to $(14,677,582) compared to the prior year.
• Cash used in operating activities for the nine months ended September 30, 2025, increased to $(14,505,325) from $(14,369,440) in the prior year, indicating a continued high cash burn rate.
• The company has an accumulated deficit of $141,875,839 as of September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, as current cash and anticipated revenues are not sufficient to fund operations for 12 months from the filing date.
• Femasys received Nasdaq deficiency letters for failing to meet the Minimum Market Value of Listed Securities (MVLS) and Minimum Bid Price requirements, risking delisting.
• Interest expense increased significantly by 28.7% for the three months and 27.5% for the nine months ended September 30, 2025, primarily due to increased non-cash discount amortization related to convertible notes.
• Interest income decreased substantially by 86.0% for the three months and 90.0% for the nine months ended September 30, 2025.
• The majority of proceeds from the November 2025 Financing will be used to repay existing convertible notes, limiting new capital for operations and development.

Risks

• Inability to obtain additional financing on acceptable terms or at all, which could materially adversely impact business, results of operations, and financial condition.
• Failure to obtain U.S. FDA approval for FemBloc, which is critical for its commercialization in the U.S. market.
• Inability to successfully grow sales of FemaSeed in the U.S. and FemBloc in the EU, UK, and other international markets.
• Challenges in achieving and maintaining adequate levels of coverage or reimbursement for products and product candidates.
• Difficulty in accurately forecasting customer demand and managing inventory effectively.
• Inability to build, manage, and maintain a direct sales and marketing organization.
• Failure to continue operating as a going concern due to persistent net operating losses and negative operating cash flows.
• Risks associated with clinical trials, including demonstrating safety and effectiveness and timely subject enrollment for FemBloc.
• Inability to manufacture products in compliance with regulations or oversee third-party suppliers effectively.
• Failure to hire and retain senior management and highly qualified personnel.
• Adverse FDA or other regulatory actions, including healthcare reform measures.
• Inability to establish and maintain intellectual property protection or avoid infringement claims.
• Volatility of the trading price of common stock.
• Risk of delisting from Nasdaq due to non-compliance with Minimum MVLS and Minimum Bid Price requirements.
• Dilution to stockholders from future equity or debt financings.
• Restrictive covenants from future debt financing that could limit operations.
• Relinquishing rights to technologies or products through collaboration and licensing arrangements if additional funding is not secured.

Future Outlook

The company expects net operating losses to increase over the next few years as it commercializes FemaSeed and FemBloc (in the EU, France, and Benelux region) and advances FemBloc through clinical development for U.S. FDA approval. Existing cash, anticipated revenues, and the November 2025 Financing are expected to fund operations into September 2026, but not for a full twelve months from the filing date, necessitating additional financing. Substantial investments are planned for ongoing commercialization, the FemBloc pivotal trial, future product development, manufacturing, regulatory affairs, post-market clinical trials, and expanding the sales and marketing organization.

Management Comments

• Management believes the company's suite of products and U.S. product candidate address multi-billion dollar global market segments with little advancement for many years, helping women avoid expensive and potentially harmful pharmaceutical solutions, implants, and surgery.
• Management expects net operating losses to increase over the next few years as the company commercializes products and advances FemBloc through clinical development.
• Management believes that after taking into account the August 2025 Financing and subsequent warrant exercises, and based on pro forma financial data, stockholders' equity as of October 15, 2025, would have been approximately $5.2 million, meeting Nasdaq's minimum requirement.

Industry Context

Femasys operates in the women's health sector, focusing on infertility and permanent birth control, areas identified as having significant unmet needs and limited recent innovation. Its strategy involves developing disruptive, accessible, in-office therapeutic and diagnostic products, contrasting with traditional surgical or pharmaceutical solutions. The global regulatory approvals for products like FemaSeed and FemBloc, coupled with strategic distribution partnerships in Europe, position the company to capitalize on international market opportunities. The introduction of FemSperm aligns with a trend towards enabling gynecologists to perform more procedures in-office, potentially increasing accessibility and reducing costs compared to specialized fertility clinics.

Comparison to Industry Standards

• The filing does not provide specific industry benchmarks or comparable companies/projects to assess results against global standards. However, FemBloc is described as a 'revolutionary first-in-class non-surgical solution' for permanent birth control, contrasting with 'centuries-old surgical sterilization' and its associated risks and costs. This implies a potential competitive advantage in terms of safety, accessibility, and cost-effectiveness compared to existing surgical methods.
• The company highlights its extensive intellectual property portfolio with over 200 issued patents globally, suggesting a strong competitive moat in its niche within women's health, which could be a differentiator against smaller players or new entrants.

Corporate Governance

Legal Proceedings

• No material legal contingencies requiring accrual or disclosure were reported for the periods presented.
• No currently pending actions against the company were reported.

Related Party Transactions

• In November 2023, the company issued a $5 million convertible note and Series A and Series B Warrants to PharmaCyte Biotech, Inc., where Joshua Silverman, PharmaCyte's interim CEO/President/Director, serves on Femasys' board of directors.
• In November 2024, Femasys paid PharmaCyte $300,000 of accrued interest on the convertible note in common stock, comprising 315,790 shares.
• In conjunction with the June 2025 Financing, certain officers and directors purchased 98,040 common shares in a private placement offering at $1.02 per share.
• In conjunction with the August 2025 Financing, certain officers purchased 87,363 common shares at $0.5151 per share.
• A family member of the CEO was employed by the company for the nine months ended September 30, 2025, and the year ended December 31, 2024.

Stakeholder Impact

• **Shareholders**: Significant dilution from multiple capital raises and warrant exercises. Risk of further dilution and potential delisting from Nasdaq could negatively impact share value. The 'going concern' doubt poses a substantial risk of complete loss of investment.
• **Employees**: Continued operations and product development offer job security, but the company's financial instability and need for ongoing financing could create uncertainty.
• **Customers**: Continued product development and commercialization of FemaSeed and FemBloc offer new and improved women's health solutions, particularly non-surgical options for permanent birth control and in-office infertility treatments.
• **Creditors**: The November 2025 financing includes senior secured convertible notes, which may offer some protection, but the company's 'going concern' doubt indicates elevated risk.
• **Suppliers**: Ongoing manufacturing and product development activities suggest continued demand for components and services, but financial instability could pose payment risks.

Next Steps

• Continue enrollment in the final phase of the FINALE pivotal trial for FemBloc in the U.S. following FDA IDE approval.
• Commercialize FemaSeed and FemBloc in the U.S., EU, UK, New Zealand, Spain, France, Benelux region, and other international markets.
• Obtain additional financing to fund ongoing operations beyond September 2026 and to complete U.S. development and EU commercialization of FemBloc.
• Monitor the common stock's bid price and consider options, including a reverse stock split, to regain compliance with Nasdaq's Minimum Bid Price Requirement by January 12, 2026.
• Continue investments in research and development for future products, manufacturing, regulatory affairs, and post-market clinical trials.
• Expand the sales and marketing organization for FemaSeed and FemBloc.
• Initiate post-market surveillance study for FemBloc in Europe.

Key Dates

Recommendation

Despite some revenue growth and product approvals, the company's financial health is severely distressed. The significant and increasing net losses, high cash burn rate, explicit 'substantial doubt about its ability to continue as a going concern,' and persistent Nasdaq delisting issues (MVLS and bid price) paint a dire picture. While recent capital raises provide temporary liquidity, a large portion is for debt repayment, and the continuous need for financing leads to substantial shareholder dilution. The long-term viability is highly questionable, and the risks far outweigh any potential upside from early-stage commercialization. A seasoned investor would recognize the severe financial instability and regulatory non-compliance as critical red flags, indicating a high probability of further share price decline and potential loss of investment.

Keywords

Women's Health, FemBloc, FemaSeed, Infertility Treatment, Permanent Birth Control, SEC Filing, 10-Q, Biomedical Innovation, FDA Approval, CE Mark, Nasdaq Compliance, Capital Raise, Clinical Trials, Medical Devices, Financial Results